Ep. 27: 3 LPR & Silent Reflux Breakthroughs Your Doctor Hasn't Mentioned Yet W/ Dr. Inna Husain
Why It Matters
Understanding pepsin’s role and emerging anti‑pepsin therapies could transform LPR management, reducing reliance on PPIs and offering relief to patients with chronic throat symptoms.
Key Takeaways
- •Pepsin can cause LPR symptoms even when acid is suppressed
- •PPIs often fail because they don’t inactivate tissue‑bound pepsin
- •Anti‑pepsin drug fosamprenavir shows promise in clinical trials
- •Laryngeal hypersensitivity involves vagus‑derived nerves and may mimic allergies
- •Speech‑language pathology and nerve blocks are first‑line LPR management
Summary
The Reflux Revolution podcast’s Episode 27 dives into emerging breakthroughs for laryngopharyngeal reflux (LPR), spotlighting three under‑discussed mechanisms—pepsin‑mediated reflux, laryngeal hypersensitivity, and vagal‑related irritation—through an interview with Dr. Inna Husain, a leading laryngologist.
Husain explains that pepsin, a non‑acidic digestive enzyme, can travel upward during reflux, embed in throat tissue, and become re‑activated by dietary acids, which accounts for persistent symptoms despite proton‑pump inhibitor (PPI) therapy. She cites research by Dr. Nikki Johnston showing pepsin’s inflammatory potential and notes that PPIs merely lower acidity without removing pepsin, limiting their efficacy.
A promising development is the repurposing of the anti‑retroviral fosamprenavir as a direct pepsin inhibitor; early clinical trials suggest it may deactivate tissue‑bound pepsin. Husain also differentiates reflux from allergic etiologies by describing endoscopic findings such as mulberry turbinate and vocal‑fold edema, while emphasizing the role of the superior lingual nerve in laryngeal hypersensitivity.
The discussion underscores a shift toward multidisciplinary care—incorporating speech‑language pathology, cough‑suppression techniques, superior lingual nerve blocks, and neuromodulators—to address both mechanical reflux and nerve‑driven symptoms. If anti‑pepsin agents prove effective, clinicians could finally target the root cause of refractory LPR, improving outcomes for millions of patients.
Comments
Want to join the conversation?
Loading comments...